Objective To explore the effects of antiretroviral therapies with TDF or TAF and without TDF and TAF on CK ⁃MB and CK in HIV/AIDS patients. Methods A retrospective analysis was conducted on newly treated HIV/AIDS patients from June 2020 to December 2020 in the outpatient department of Changsha First Hospital. The general data of 365 HIV/AIDS patients were analyzed. Levels of CK ⁃ MB and CK at baseline and weeks 12，24，and 48 were collected respectively，so were the baseline and 48⁃week electrocardiogram and color Doppler echocardiography. Results Among 365 HIV/AIDS patients，326 were male and 39 were female. The aver⁃ age age was（32.56 ± 10.20）years. CK ⁃MB was different in different treatment periods（F = 26.58，P < 0.05）. There was interaction between different antiviral treatment periods and antiviral regimens（F = 95.57，P < 0.05）. There was a difference in CK⁃MB among different antiviral regimens（F = 174.98，P < 0.05），in which the CK⁃MB in the TDF⁃containing group became higher and higher as the prolonged treatments. There was no difference in CK among different treatment periods（F = 3.14，P = 0.07）. There was no interaction between different antiviral regi⁃ mens and antiviral regimens（F = 1.81，P = 0.16）. However，there were differences in CK among different antivi⁃ ral regimens（F = 4.47，P = 0.01）. There was no statistical difference in the incidence of ECG abnormalities at baseline and week 48 among different ART protocols（χ2 = 0.58，P = 0.75；χ2 = =3.14，P = 0.21）. There was no statistical difference in the incidence of cardiac color ultrasound abnormalities at baseline and week 48 between different ART protocols（χ2 = 1.32，P = 0.52；χ2 = 0.58，P = 0.75）. Conclusions Different anti⁃virus therapies have impacts on CK ⁃MB and CK in HIV/AIDS patients，especially the TDF ⁃ containing therapy shows a greater impact，but it has no significant impact on ECG and cardiac color ultrasound.